Hospitalization Rates in Patients with Heart Failure and Reduced Ejection Fraction Initiating Sacubitril/Valsartan or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: A Retrospective Cohort Study

INTRODUCTION: The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan (SAC/VAL) has shown benefit in patients with symptomatic heart failure (HF), including those naïve to renin–angiotensin–aldosterone system inhibitor (RAASi) therapy, and is considered the preferred RAASi for chro...

Descripción completa

Detalles Bibliográficos
Autores principales: Houchen, Emma, Loefroth, Emil, Schlienger, Raymond, Proudfoot, Clare, Corda, Stefano, Saha, Sibasish, Satwase, Sarvesh K., Studer, Rachel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800553/
https://www.ncbi.nlm.nih.gov/pubmed/35094306
http://dx.doi.org/10.1007/s40119-021-00252-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800553/
https://www.ncbi.nlm.nih.gov/pubmed/35094306
http://dx.doi.org/10.1007/s40119-021-00252-4

Ejemplares similares